The mechanism and potential targets of class II HDACs in angiogenesis

Hou, Fei; Li, Dandan; Yu, Honglian; Kong, Qingsheng

doi:10.1002/jcb.26476

Cited by 8 publications

(2 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After the expression of HDAC3 is reduced by the inhibitors, the growth and invasive ability of human glioma cell appears significantly weakened, which provides a new way for the cancer treatment (Zhong et al,2018). HDAC4, HDAC5, HDAC7, and HDAC9 belong to Class II of HDACs (Hou et al,2018). HDAC4 is frequently dysregulated in human malignancies, and we also confirmed the downregulated expression in glioma tissues.…”

Section: Discussionsupporting

confidence: 71%

Comprehensive analysis of Histone deacetylases genes in the prognosis and immune infiltration of glioma patients

Liu

Shen

et al. 2022

Preprint

View full text Add to dashboard Cite

Background The occurrence and development of tumors are closely related to histone deacetylases (HDACs). However,the overall biology and prognosis are still unknown in glioma. In the present study,we comprehensively explored the biology function and prognosis of eleven HDAC genes in glioma,which may contribute the more understanding of molecular mechanisms and potential therapeutic targets for glioma patients. Methods We systematically described the expression files, molecular subtypes, prognostic value,immune filtration and tumor microenvironment and gene alteration,function and pathways enrichment,and drug sensitivity using TCGA and CGGA datasets. We developed and validated the prognostic model based on HDACs genes in glioma using LASSO,univariate, and multivariate cox regression. Receiver operating characteristic analyses were used for model evaluating. We also validated the expressions of HDACs genes included in the model in non-tumor and glioma tissues samples. Results Glioma patients can be divided into two subclasses based on eleven HDAC genes, and patients from two subclasses had markedly different survival outcomes. Then, using six HDAC genes (HDAC1, HDAC3, HDAC4, HDAC5, HDAC7, and HDAC9), we established a prognostic model in glioma patients, and this prognostic model was well validated in an independent cohort population. Furthermore, the calculated risk score from six HDACA genes expression was suggested to be an independent prognostic factor, which can predict the five-year overall survival of glioma patients well. High-risk patients can be attributed to multiple complex function and molecular signaling pathways, and the genes alterations of high- and low-risk patients were significantly different. We also found that different survival outcomes of high- and low- risk patients could be involved in the differences of immune filtration level and tumor microenvironment. Subsequently, we identified several small molecular compounds that could be favorable for glioma patients treatment. And finally, the expression levels of HDAC genes from prognostic model were validated in glioma and non-tumor tissues samples. Conclusion Our results revealed the clinical utility and potential molecular mechanisms of HDAC genes in glioma. Model based on six HDAC genes can predict the overall survival of glioma patients well, which can be served as potential therapeutic targets.

show abstract

Section: Discussionsupporting

confidence: 71%

Comprehensive analysis of Histone deacetylases genes in the prognosis and immune infiltration of glioma patients

Liu

Shen

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…HDAC4, HDAC5, HDAC7, and HDAC9 are Class II HDACs [ 25 ]. HDAC4 is frequently dysregulated in human malignancies, and we also confirmed its downregulated expression in glioma tissues.…”

Section: Discussionmentioning

confidence: 99%

Comprehensive analysis of histone deacetylases genes in the prognosis and immune infiltration of glioma patients

Shen

et al. 2022

Aging

View full text Add to dashboard Cite

The occurrence and development of tumors are closely related to histone deacetylases (HDACs). However, their relationship with the overall biology and prognosis of glioma is still unknown. In the present study, we developed and validated a prognostic model for glioma based on HDAC genes. Glioma patients can be divided into two subclasses based on eleven HDAC genes, and patients from the two subclasses had markedly different survival outcomes. Then, using six HDAC genes (HDAC1, HDAC3, HDAC4, HDAC5, HDAC7, and HDAC9), we established a prognostic model for glioma patients, and this prognostic model was validated in an independent cohort. Furthermore, the calculated risk score from six HDACA genes expression was found to be an independent prognostic factor that could predict the five-year overall survival of glioma patients well. High-risk patients have changes in multiple complex functions and molecular signaling pathways, and the gene alterations of high- and low-risk patients were significantly different. We also found that the different survival outcomes of high- and low-risk patients could be related to the differences in immune filtration levels and the tumor microenvironment. Subsequently, we identified several small molecular compounds that could be favorable for glioma patient treatment. Finally, the expression levels of HDAC genes from the prognostic model were validated in glioma and nontumor tissue samples. Our results revealed the clinical utility and potential molecular mechanisms of HDAC genes in glioma. A model based on six HDAC genes can predict the overall survival of glioma patients well, and these genes are potential therapeutic targets.

show abstract

Design, synthesis, and in vitro biological evaluation of novel HDAC inhibitors bearing C-1 phenyl substituted tetrahydroisoquinoline Cap moiety as anti-tumor therapeutic agents

Wang,

Zhou,

et al. 2024

Med Chem Res

View full text Add to dashboard Cite

The mechanism and potential targets of class II HDACs in angiogenesis

Cited by 8 publications

References 72 publications

Comprehensive analysis of Histone deacetylases genes in the prognosis and immune infiltration of glioma patients

Comprehensive analysis of Histone deacetylases genes in the prognosis and immune infiltration of glioma patients

Comprehensive analysis of histone deacetylases genes in the prognosis and immune infiltration of glioma patients

Design, synthesis, and in vitro biological evaluation of novel HDAC inhibitors bearing C-1 phenyl substituted tetrahydroisoquinoline Cap moiety as anti-tumor therapeutic agents

Contact Info

Product

Resources

About